immusmol-小分子抗体供应商

immusmol是由Alban Bessede博士于2012年在法国创立，ImmuSmol设计和开发了能够靶向900道尔顿以下低分子量小分子的抗体，例如氨基酸代谢物、脂质、糖类、毒素、类固醇等。小分子抗体与现有的基于抗体的技术wan全兼容，在研究、诊断和治疗应用中开辟了一系列全新的可能性。immusmol团队由大约20名不同背景和应用领域的人才组成，将他们的专业知识和经验带到公司。immusmol旨在成为小分子抗体开发的shou选。

immusmol提供经过验证的小分子抗体和ELISA试剂盒。抗体通过ELISA的特异性和亲和力进行选择，能够快速、可靠地检测和/或定量各种类型的生物材料中的小分子，包括细胞和裂解物、组织和匀浆、培养上清液、血浆和血清样品。

Immusmol针对靶标领域：

使用immusmol产品发表的部分文献：

1. Lalitsuradej et al., 2022. Correlation between nicotine dependence and inflammatory biomarkers in Thai smokers: eight weeks of synbiotic intervention. IAES International Journal of Artificial Intelligence (IJ-AI), 11 (4): 1414-1425.

2. Park et al., 2022. Priming Mesenchymal Stem/Stromal Cells with a Combination of a Low Dose of IFN- and Bor_tezomib Results in Potent Suppression of Pathogenic Th17 Immunity Through the IDO1-AHR Axis. Stem Cells, 41 (1): 64-76.

3. Silvano et al., 2022. Tryptophan degradation enzymes and Angiotensin (1−7) expression in human placenta. Journal of Reproductive Immunology, 153: 103692.

4. Struckmeier et al., 2022. IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma. Journal of Cancer Reasearch & Clinical Oncology, 149: 3623-3635.

5. Gargaro et al., 2022. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity, 55 (6): 1032-1050.

6. Uefune et al., 2022. Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer. Diabetes, 71 (9): 1946-1961.

7. Siska et al., 2022. Kynurenine induces T cell fat catabolism and has limited suppressive effects in vivo. eBioMedicine, 74: 103734.

8. Hur et al., 2022. Mepirapim, a Novel Synthetic Cannabinoid, Induces Addiction-Related Behaviors through Neurochemical Maladaptation in the Brain of Rodents. Pharmaceuticals,15 (6), 710.

9. Pfanzagl et al., 2022. Histamine via histamine H1 receptor enhances the muscarinicreceptor-induced calcium response to acetylcholine in anenterochromaffin cell model. Clinical & Experimental Pharmacology & Physiology, 49 (10): 1059-1071.

10. Peyraud et al., 2022. Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Annals of oncology, 33 (10): 1041-1051.

immusmol热卖产品

作为immusmol在中国区域的代理，上海金畔生物科技有限公司将为中国客户提供zui全面的immusmol的产品。欢迎大家随时联系我们！！！